TY  - JOUR
AU  - De Laurentiis, Michelino
AU  - Borstnar, Simona
AU  - Campone, Mario
AU  - Warner, Ellen
AU  - Bofill, Javier Salvador
AU  - Jacot, William
AU  - Dent, Susan
AU  - Martin, Miguel
AU  - Ring, Alistair
AU  - Cottu, Paul
AU  - Lu, Janice
AU  - Ciruelos, Eva
AU  - Azim, Hamdy A
AU  - Chatterjee, Sanjoy
AU  - Zhou, Katie
AU  - Wu, Jiwen
AU  - Menon-Singh, Lakshmi
AU  - Zamagni, Claudio
PY  - 2021
DO  - 10.1007/s10549-021-06334-0
UR  - http://hdl.handle.net/10668/18396
T2  - Breast cancer research and treatment
AB  - CompLEEment-1 is a phase 3b trial in an expanded patient population with hormone receptor-positive (HR +), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC), the largest current trial of cyclin-dependent kinase 4...
LA  - en
KW  - Advanced breast cancer
KW  - CDK4/6 inhibitor
KW  - Endocrine therapy
KW  - Ribociclib
KW  - Aminopyridines
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Breast Neoplasms
KW  - Female
KW  - Humans
KW  - Letrozole
KW  - Purines
KW  - Quality of Life
KW  - Receptor, ErbB-2
KW  - Receptors, Estrogen
KW  - Receptors, Progesterone
TI  - Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population.
TY  - research article
VL  - 189
ER  -